Form 8-K - Current report:
SEC Accession No. 0001683168-21-006502
Filing Date
2021-12-22
Accepted
2021-12-22 08:01:47
Documents
14
Period of Report
2021-12-20
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT sunshine_8k.htm   iXBRL 8-K 26142
2 PRESS RELEASE sunshine_ex9901.htm EX-99.1 10889
3 GRAPHIC image_001.jpg GRAPHIC 11814
  Complete submission text file 0001683168-21-006502.txt   228265

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE sbfm-20211220.xsd EX-101.SCH 3052
5 XBRL LABEL FILE sbfm-20211220_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE sbfm-20211220_pre.xml EX-101.PRE 22377
8 EXTRACTED XBRL INSTANCE DOCUMENT sunshine_8k_htm.xml XML 3507
Mailing Address 6500 TRANS-CANADA HIGHWAY 4TH FLOOR POINTE-CLAIRE A8 H9R 0A5
Business Address 6500 TRANS-CANADA HIGHWAY 4TH FLOOR POINTE-CLAIRE A8 H9R 0A5 514-426-6161
Sunshine Biopharma, Inc (Filer) CIK: 0001402328 (see all company filings)

EIN.: 205566275 | State of Incorp.: CO | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-52898 | Film No.: 211511023
SIC: 8731 Services-Commercial Physical & Biological Research